A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study of parsaclisib plus BR versus placebo plus BR as first-line treatment of participants with newly diagnosed MCL.
Epistemonikos ID: 98104b4f8e753cbe1d8491c120be9b017c8e240f
First added on: May 08, 2024